Related Experiment Videos
Decreased circulating levels of ANGPTL8 in Graves' disease patients
Haoxiang Li1, Mengjiao Xu1, Li Zhao1
1Department of Endocrinology, Affiliated Hospital of Jiangsu University, 438, Jiefang Road, Zhenjiang, 212001, Jiangsu, China.
Background:
Angiopoietin-like protein 8 (ANGPTL8), a newly identified hormone, has been recently characterized as a metabolic regulator which can affect energy homeostasis and has interesting potentials as a metabolic disease therapy. However, little is as yet known as to whether circulating ANGPTL8 levels are altered in thyroid dysfunction. This study measured serum ANGPTL8 levels in patients with Graves' disease and explored the correlations between its serum levels and thyroid index in Graves' disease.
Methods:
The concentration of ANGPTL8 was analyzed in blood samples of 128 well-characterized individuals whose anthropometric parameters, biochemical parameters, and thyroid index were measured. The participants were divided into Graves' disease patients (n = 60) and healthy control subjects (n = 68). Logistic regression was used to evaluate the relationship between ANGPTL8 and Graves' disease.
Results:
Serum ANGPTL8 levels were more significantly decreased in Graves' disease patients than in healthy control subjects (177.67 ± 135.07 vs 326.41 ± 194.72 pg/mL; p < 0.001). Serum ANGPTL8 was negatively correlated with free triiodothyronine (FT3), free thyroxine (FT4), and thyroid peroxidase antibodies (TPOAb) while being positively correlated with thyrotropin (TSH). Logistic regression analyses demonstrated that serum ANGPTL8 was significantly associated with Graves' disease (p < 0.05).
Conclusions:
Circulating concentrations of ANGPTL8 showed a significant reduction in Graves' disease patients. Thus, it is suggested that thyroid function should be taken into consideration when evaluating the results of ANGPTL8.
Insights
Serum levels of Angiopoietin-like protein 8 (ANGPTL8) are significantly reduced in patients with Graves' disease. This finding suggests ANGPTL8 may serve as a biomarker for thyroid dysfunction, impacting metabolic regulation.
Area of Science:
- Endocrinology
- Metabolic Regulation
- Thyroid Disorders
Background:
- Angiopoietin-like protein 8 (ANGPTL8) is a novel metabolic regulator with therapeutic potential.
- Its role in thyroid dysfunction, specifically Graves' disease, remains largely unexplored.
- This study investigates circulating ANGPTL8 levels in Graves' disease patients.
Purpose of the Study:
- To measure serum ANGPTL8 concentrations in individuals with Graves' disease.
- To compare ANGPTL8 levels between Graves' disease patients and healthy controls.
- To explore correlations between serum ANGPTL8 and key thyroid function indices.
Main Methods:
- Serum ANGPTL8 levels were quantified in 128 participants (60 Graves' disease patients, 68 controls).
- Anthropometric, biochemical, and thyroid function parameters were assessed.
- Logistic regression analysis was employed to determine the association between ANGPTL8 and Graves' disease.
Main Results:
- Graves' disease patients exhibited significantly lower serum ANGPTL8 levels compared to controls (177.67 ± 135.07 vs 326.41 ± 194.72 pg/mL; p < 0.001).
- Serum ANGPTL8 showed negative correlations with free triiodothyronine (FT3), free thyroxine (FT4), and thyroid peroxidase antibodies (TPOAb).
- A positive correlation was observed between ANGPTL8 and thyrotropin (TSH), with ANGPTL8 significantly associated with Graves' disease (p < 0.05).
Conclusions:
- Circulating ANGPTL8 concentrations are significantly reduced in patients with Graves' disease.
- These findings suggest ANGPTL8 may be a potential biomarker for thyroid dysfunction.
- Thyroid function status should be considered when interpreting ANGPTL8 levels.